皮肤基因表达可预测弥漫性皮肤型系统性硬化症患者皮肤病变的轨迹
研究分析了38例安慰剂治疗的早期弥漫性皮肤型系统性硬化症(dcSSc)患者的皮肤活检基因表达,发现基线CD14、SERPINE1、IL13RA1、CTGF和OSMR高表达者更易出现皮肤评分进展性轨迹,其中IL13RA1、OSMR和SERPINE1预测能力最佳。这些生物标志物或有助于指导侵袭性治疗和临床试验的患者选择。
要点
- 基线皮肤CD14、SERPINE1、IL13RA1、CTGF和OSMR高表达与进展性皮肤评分轨迹相关。
- IL13RA1、OSMR和SERPINE1对皮肤进展风险的预测能力最佳。
- 巨噬细胞(CD14、IL13RA1)和TGF-β活化(SERPINE1、CTGF、OSMR)相关标志物具预后价值。
核心结论
- 与巨噬细胞(CD14、IL13RA1)和转化生长因子β活化(SERPINE1、CTGF、OSMR)相关的皮肤基因表达对dcSSc患者进展性皮肤病变具有预后价值。
- 这些生物标志物或可为决定哪些患者考虑侵袭性治疗和/或临床试验提供指导。
研究设计与样本
- 研究分析了38例安慰剂治疗的早期dcSSc患者的临床数据和皮肤活检样本基因表达,样本来自罗氏托珠单抗治疗SSc的FASSCINATE II期研究。
- RNA样本采用nCounter分析,基于改良Rodnan皮肤厚度评分构建轨迹模型描述3种皮肤病变轨迹,采用卡方检验分析皮肤基因表达与皮肤评分轨迹组的关联,采用逻辑回归分析每个基因的预后能力。
主要发现
- 基线时CD14、SERPINE1、IL13RA1、CTGF和OSMR信使RNA高表达的安慰剂治疗患者更可能出现进展性皮肤评分轨迹。
- 这些基因对皮肤进展风险具有预后价值,其中IL13RA1、OSMR和SERPINE1表现最佳。
临床怎么用
- 作者认为这些生物标志物或可为决定哪些患者考虑侵袭性治疗和/或临床试验提供指导。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: At present, there are no clinical or laboratory measures that accurately forecast the progression of skin fibrosis and organ involvement in patients with systemic sclerosis (SSc). The goal of this study was to identify skin biomarkers that could be prognostic for the progression of skin fibrosis in patients with early diffuse cutaneous SSc (dcSSc). METHODS: We analyzed clinical data and gene expression in skin biopsy samples from 38 placebo-treated patients, part of the Roche Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis (FASSCINATE) phase II study of tocilizumab in SSc. RNA samples were analyzed using nCounter. A trajectory model based on a modified Rodnan skin thickness score was used to describe 3 skin disease trajectories over time. We examined the association of skin gene expression with skin score trajectory groups, by chi-square test. Logistic regression was used to examine the prognostic power of each gene identified. RESULTS: We found that placebo-treated patients with high expression of messenger RNA for CD14, SERPINE1, IL13RA1, CTGF, and OSMR at baseline were more likely to have progressive skin score trajectories. We also found that those genes were prognostic for the risk of skin progression and that IL13RA1, OSMR, and SERPINE1 performed the best. CONCLUSION: Skin gene expression of biomarkers associated with macrophages (CD14, IL13RA1) and transforming growth factor β activation (SERPINE1, CTGF, OSMR) are prognostic for progressive skin disease in patients with dcSSc. These biomarkers may provide guidance in decision-making about which patients should be considered for aggressive therapies and/or for clinical trials.
引用
- Stifano G, Sornasse T, Rice LM, et al. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2018. PMID: 29858547. doi:10.1002/art.40455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。